Rapid inhibition of thyroxine-induced bone resorption in the rat by an orally active vitronectin receptor antagonist.
An excess of thyroid hormone results in increased bone turnover and loss of bone mass in humans. Exogenous administration of thyroid hormone to rats has served as a model of human hyperthyroidism in which antiresorptive therapies have been tested. We have further refined this model of thyroxine (T4)-induced turnover in the rat. Daily administration of T4 to aged rats for as short as 1 week resulted in elevated bone resorption determined by significantly higher urinary deoxypyridinoline (Dpd) compared with vehicle controls or animals receiving T4 plus estradiol. Three weeks of daily administration of T4 led to significantly lower bone mineral density compared with untreated controls or animals receiving T4 plus estradiol. In a follow-up study, a depot formulation of T4 caused an increase in Dpd identical to that achieved with a bolus dose. SB-273005 [(4S)-2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl] ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-1H-2-benzazepine-4- acetic acid] a potent antagonist of the integrins alpha(v)beta(3) and alpha(v)beta(5), has been shown previously to inhibit bone resorption in cultures of human osteoclasts and to protect bone in ovariectomized rats. The effect of SB-273005 by oral administration was evaluated in this thyroxine-induced turnover model. Dose-dependent inhibition of resorption was seen with SB-273005 after 7 days of dosing using Dpd as a measure of bone resorption. In summary, it has been demonstrated that the antiresorptive activity of a vitronectin receptor antagonist can be measured after only 7 days of treatment in this refined rat model of thyroxine-induced bone turnover. These data suggest that SB-273005 may be useful for the treatment of metabolic bone diseases, including those resulting from hyperthyroidism.
Hoffman
Sandra J
SJ
Department of Musculoskeletal Diseases, GlaxoSmithKline, Mail Code UW2109, 709 Swedeland Road, PO Box 1539, King of Prussia, PA 19406, USA. Sandra_J_Hoffman@gsk.com
Vasko-Moser
Janice
J
Miller
William H
WH
Lark
Michael W
MW
Gowen
Maxine
M
Stroup
George
G
D000596:Amino Acids / Q000652:urine; D000818:Animals; D015415:Biomarkers; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D015675:Osteocalcin / Q000097:blood; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors*; D013974:Thyroxine / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000633:toxicity; D014284:Triiodothyronine / Q000378:metabolism
D000596:Amino Acids; D015415:Biomarkers; D011725:Pyridines; D019030:Receptors, Vitronectin; C420822:SB 273005; D014284:Triiodothyronine; D015675:Osteocalcin; C036020:deoxypyridinoline; D013974:Thyroxine